{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:49:48Z","timestamp":1791434988620,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.farma.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:06:20Z","timestamp":1791432380000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dalbavancin and oritavancin in long-term suppressive therapy: Use, safety, dosing regimens and the role of therapeutic drug monitoring, protocol for a systematic review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7849-124X","authenticated-orcid":false,"given":"Raquel","family":"Gil-Bardaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-7359","authenticated-orcid":false,"given":"Carla","family":"Codina-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Martin Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Bosch-Peligero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diez de los Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-6087","authenticated-orcid":false,"given":"Esteban","family":"Reynaga Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"\u00c1lvarez Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-6504","authenticated-orcid":false,"given":"Sergio","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.farma.2026.08.012_bb0005","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.farma.2026.08.012_bb0010","article-title":"Genomic and phenotypic adaptations of methicillin resistant Staphylococcus aureus during vancomycin therapy","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.farma.2026.08.012_bb0015","series-title":"Xydalba\u00ae(dalbavancin)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.farma.2026.08.012_bb0020","series-title":"Tenkasi\u00ae (oritavancin)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.farma.2026.08.012_bb0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.farma.2026.08.012_bb0030","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/antibiotics13111063","article-title":"Safety and efficacy of dalbavancin in real life: retrospective analysis of a large monocentric case series of patients treated for skin\/soft tissue and other difficult-to-treat infections","volume":"13","author":"Parruti","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.farma.2026.08.012_bb0035","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s15010-024-02176-2","article-title":"In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry","volume":"52","author":"Esposito","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.farma.2026.08.012_bb0040","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.farma.2026.08.012_bb0045","first-page":"1222","article-title":"The current and future off-label uses of dalbavancin: a narrative review","volume":"27","author":"De Vito","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.farma.2026.08.012_bb0050","article-title":"Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections","volume":"0","author":"Cojutti","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.farma.2026.08.012_bb0055","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10096-024-04849-0","article-title":"Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature","volume":"43","author":"Lafon-Desmurs","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.farma.2026.08.012_bb0060","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3390\/antibiotics12050937","article-title":"Chronic suppressive antibiotic treatment for staphylococcal bone and joint implant-related infections","volume":"12","author":"Ceccarelli","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.farma.2026.08.012_bb0065","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.farma.2026.08.012_bb0070","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.farma.2026.08.012_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-99112-7","article-title":"Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus","volume":"15","author":"Morath","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.farma.2026.08.012_bb0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.farma.2026.08.012_bb0085","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.farma.2026.08.012_bb0090","unstructured":"Gil-Bardaji R, Codina-Jimenez C, Martin Val A, et al. The use of dalbavancin and oritavancin as long-term suppressive therapy: a systematic review. PROSPERO: International Prospective Register of Systematic Reviews. 2025. CRD420251054127. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=136245."},{"key":"10.1016\/j.farma.2026.08.012_bb0095","series-title":"Critical appraisal tools","author":"Joanna Briggs Institute","year":"2026"},{"key":"10.1016\/j.farma.2026.08.012_bb0100","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:06:25Z","timestamp":1791432385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326002175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"alternative-id":["S1130634326002175"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.08.012","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin and oritavancin in long-term suppressive therapy: Use, safety, dosing regimens and the role of therapeutic drug monitoring, protocol for a systematic review","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}